Year | Patient-level data | Published data | Sponsor | Type of publication |
---|---|---|---|---|
Treatment A (trial name; ClinicalTrials.gov identifier) | Treatment B (trial name; ClinicalTrials.gov identifier) | |||
Ankylosing spondylitis | ||||
2016 | Secukinumab (MEASURE 2; NCT01649375) | Adalimumab (ATLAS; NCT00195819) | Novartis | Abstract [5] |
2016 | Adalimumab (ATLAS; NCT00195819) | Secukinumab (pooled MEASURE 1 [NCT01358175], MEASURE 2 [NCT01649375]) | Abbvie | Abstract [6] |
2016 | Secukinumab (MEASURE 2; NCT01649375) | Adalimumab (ATLAS; NCT00195819) | Novartis | Abstract [7] |
2016 | Secukinumab (MEASURE 1; NCT01358175) | Adalimumab (ATLAS; NCT00195819) | Novartis | Abstract [8] |
2016 | Secukinumab (pooled MEASURE 1 [NCT01358175], MEASURE 2 [NCT01649375]) | Adalimumab (ATLAS; NCT00195819) | Novartis | Abstract [9] |
2017 | Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) | Golimumab (GO-RAISE; NCT00265083) | Novartis | Abstract [10] |
2017 | Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) | Golimumab (GO-RAISE; NCT00265083) | Novartis | Abstract [11] |
2017a | Secukinumab (MEASURE 2; NCT01649375) | Adalimumab (ATLAS; NCT00195819) | Novartis | Abstract [12] |
Psoriatic arthritis | ||||
2013 | Adalimumab (ADEPT; NCT00195689) | Etanercept (Mease et al. 2004), infliximab (IMPACT 2; NCT00051623) | Abbvie | Manuscript [13] |
2015 | Adalimumab (ADEPT; NCT00195689) | Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) | Abbvie | Abstract [14] |
2016 | Secukinumab (FUTURE 2; NCT01752634) | Adalimumab (ADEPT; NCT00195689) | Novartis | Abstract [15] |
2016 | Secukinumab (FUTURE 2; NCT01752634) | Adalimumab (ADEPT; NCT00195689) | Novartis | Abstract [16] |
2016 | Secukinumab (FUTURE 2; NCT01752634) | Etanercept (Mease et al. 2004) | Novartis | Abstract [17] |
2016 | Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) | Adalimumab (ADEPT; NCT00195689) | Novartis | Abstract [18] |
2016 | Secukinumab (FUTURE 2; NCT01752634) | Infliximab (IMPACT 2; NCT00051623) | Novartis | Abstract [19] |
2016a | Secukinumab (FUTURE 2; NCT01752634) | Adalimumab (ADEPT; NCT00195689) | Novartis | Abstract [20] |
2017 | Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) | Interferon (IMPACT 2; NCT00051623) | Novartis | Abstract [21] |
2017a | Secukinumab (FUTURE 2; NCT01752634) | Infliximab (IMPACT 2; NCT00051623) | Novartis | Abstract [22] |
2017a | Secukinumab (FUTURE 2; NCT01752634) | Etanercept (Mease et al. 2004) | Novartis | Abstract [23] |
2017a | Secukinumab (FUTURE 2; NCT01752634) | Adalimumab (ADEPT; NCT00195689) | Novartis | Abstract [24] |
2017 | Adalimumab (ADEPT; NCT00195689) | Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634]) | Abbvie | Manuscript [25] |